Clinical trials: Alzheimer Disease Dementia
Alzheimer's Disease
Computerized Cognition Testing in Participants With Mild Alzheimer's Disease (AD) Treated With Donepezil (MK-0000-318)
This study aims to determine whether the Cogstate testing battery can detect improvements in cognitive function in participants with mild AD.
- Trial name
- NCT02064920
- Testing
- Donepezil
- Volunteers
- 36 people
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer Disease
Study to Compare the Pharmacokinetics of Daily Administration of Tricaprilin on Ketone Body Production
This is a Phase I, single center, open label, multiple dose, pharmacokinetic (PK) study recruiting healthy older subjects.
- Trial name
- NCT04268953
- Testing
- Tricaprilin
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Cerecin
Dementia, Alzheimer Disease
A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia
The purpose of the study is to compare the safety and efficacy of risperidone (an antipsychotic medication) to that of placebo in the treatment of behavioral disturbances associated with dementia.
- Conditions
- Dementia, Alzheimer Disease, Dementia, Vascular
- Trial name
- NCT00249145
- Testing
- risperidone
- Volunteers
- 349 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Alzheimer Disease
Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Donepezil From Single Dose of GB-5001 IM Depot and Aricept® Oral Tablets in Healthy Male Volunteers
This study is to evaluate the safety and tolerability of single dose of GB-5001 (donepezil) IM depot in healthy male volunteers.
- Trial name
- NCT05525780
- Testing
- GB-5001, Oral cohort
- Where
- Canada
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- G2GBio, Inc.
Alzheimer Disease, Mild Cognitive Impairment
Dementia Signal Development Study of Nautilus NeuroWave TM for the Detection of Dementia
This study is being performed to generate data regarding brain vibration /oscillation differences between individuals with dementia and normal controls.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Frontotemporal Lobar Degeneration, Memory Disorders
- Trial name
- NCT02333942
- Testing
- Nautilus NeuroWaveTM System
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Jan Medical, Inc.
Alzheimer Disease
Pharmacokinetic Properties of Idalopirdine (Lu AE58054) in Subjects With and Without Impaired Kidney Function
The purpose of this study is to evaluate the pharmacokinetics properties of idalopirdine following multiple dosing in patients with renal impairment and compare to those in healthy subjects
- Trial name
- NCT02340195
- Testing
- Idalopirdine (Lu AE58054) 60 mg
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Alzheimer Disease
Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease
A 76-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants with mild-to-moderate Alzheimer's disease (AD) for 76 weeks.
- Trial name
- REFOCUS-ALZ (NCT05026177)
- Testing
- Simufilam
- Where
- 89 sites in United States, Canada and 2 more
- Volunteers
- 1,125 people
- Sponsor
- Cassava Sciences, Inc.
Alzheimer Disease
Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease
The primary purpose of this long-term follow-up study is to assess the long-term safety profile of APOE4 homozygote participants who were administered gene therapy (LX1001) for the treatment of Alzheimer's disease in Study…
- Trial name
- LEADLTFU (NCT05400330)
- Testing
- LX1001
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Lexeo Therapeutics
Healthy
A Safety, Tolerability and Pharmacokinetics Study of JNJ-54861911 in Healthy Japanese Male Participants
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK, study of the way a drug enters and leaves the blood and tissues over time) of single-ascending oral doses of JNJ-54861911 in healthy…
- Trial name
- NCT02180269
- Testing
- JNJ-54861911 (25 mg), JNJ-54861911 (50 mg), JNJ-54861911 (100 mg)
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Janssen Pharmaceutical K.K.
Alzheimer's Disease
Preliminary Efficacy and Safety Study of ST101 in Alzheimer's Disease
This study will investigate the ability of ST101 to improve memory in people with Alzheimer's disease. This study also will examine the safety and tolerability of the drug.
- Trial name
- NCT00842673
- Testing
- ST101
- Where
- 18 sites in United States, Canada
- Volunteers
- 168 people
- Sponsor
- Sonexa Therapeutics, Inc.
Alzheimer Disease, Dementia
Assistive Technology and Reduced Caregiver Burden
The study investigated a six-week randomized controlled trial study in a small cohort of 16 family caregivers of individuals living with Alzheimer's disease and related dementias.
- Conditions
- Alzheimer Disease, Dementia, Caregiver Burden, Quality of Life
- Trial name
- ck (NCT05352529)
- Testing
- The MapHabit system, Dementia educational videos
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- MapHabit, Inc.
Alzheimer Disease, Alzheimer Disease (AD)
Phase I Clinical Study of AV-1959R: Abeta-targeting Anti-Alzheimer's Vaccine
This Phase 1 clinical trial evaluates the safety, tolerability, and immune response of the adjuvanted AV-1959R vaccine in healthy adults aged 40-60.
- Conditions
- Alzheimer Disease, Alzheimer Disease (AD), Alzheimers Disease Prevention
- Trial name
- NCT06831812
- Testing
- AV-1959R (Abeta vaccine)
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Nuravax, Inc.
AD, Early Alzheimer's Disease
A Study to Evaluate the Efficacy and Safety of TTYP01 Tablets in Early Symptomatic Alzheimer's Disease
This is a multicenter, randomized, double-blind, placebo-controlled parallel Phase II core period study to evaluate the efficacy and safety of TTYP01 Tablets in early symptomatic AD (Mild cognitive impairment [MCI] due to AD, or…
- Trial name
- NCT07252440
- Testing
- TTYP01 tables 60mg, TTYP01 tables 90mg, TTYP01 tables 0mg
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Shanghai Auzone Biological Technology Co., Ltd.
Agitation in Dementia, Including Alzheimer's Disease
ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease
This is a randomized, double-blind, placebo-controlled study comparing the efficacy and safety of ITI-007 versus placebo administered orally once daily in the treatment of agitation in patients with dementia, including…
- Trial name
- NCT02817906
- Testing
- ITI-007
- Where
- 26 sites in United States
- Volunteers
- 177 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Alzheimer's Disease
Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate Alzheimers
This is a Phase III, multicenter, open-label extension, single-group study in male and female outpatients with mild-to-moderate Alzheimer's disease (AD) who have completed either AVA102670 or AVA102672.
- Trial name
- NCT00490568
- Testing
- Rosiglitazone XR
- Where
- 272 sites in United States, Argentina and 27 more
- Volunteers
- 1,461 people
- Sponsor
- GlaxoSmithKline
Alzheimer's Disease
Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients
This study will assess the safety, tolerability and Abeta-specific antibody response of repeated intra-muscular injections of adjuvanted CAD106 in patients with mild Alzheimer's Disease.
- Trial name
- NCT01097096
- Testing
- CAD106, Alum, MF59
- Where
- 31 sites in United States, Belgium and 8 more
- Volunteers
- 177 people
- Sponsor
- Novartis Pharmaceuticals
Dementia, Alzheimer Disease
The BRAIN App (Phase 2 SBIR)
There are currently 6.7 million Americans living with dementia and, without significant breakthroughs, this figure will double to 12.7 million by 2050. There are about 46,000 long-term care (LTC) facilities in the U.S.
- Conditions
- Dementia, Alzheimer Disease, Vascular Dementia
- Trial name
- NCT06298474
- Testing
- The BRAIN App
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Hopeful Aging
Alzheimer's Disease
Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012)
The purpose of this multicenter trial is to assess the efficacy and safety of MK-7622 compared with placebo as adjunctive therapy to acetylcholinesterase inhibitors (AChEIs) for the symptomatic treatment of participants with mild…
- Trial name
- NCT01852110
- Testing
- MK-7622, AChEI
- Volunteers
- 240 people
- Sponsor
- Merck Sharp & Dohme LLC
Dementia, Alzheimer Type
Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type
The primary objective of the study is to compare the efficacy of aripiprazole with placebo in patients with psychosis associated with Alzheimer's dementia.
- Trial name
- NCT01438060
- Testing
- Aripiprazole (BMS-337039)
- Volunteers
- 232 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Alzheimer's Disease, Mild Cognitive Impairment
Diagnosis and Monitoring of Disease Progression Using Deep Neuro Signatures
Alzheimer's disease (AD) clinically characterized by the cognitive impairment and lowering of various functional abilities lead to staggering costs and suffering, which are particularly related to the social impacts of caring for…
- Trial name
- DNS (NCT05153941)
- Where
- Greece
- Volunteers
- 3,500 people, healthy volunteers welcome
- Sponsor
- Altoida
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.